Zura Bio Ltd (ZURA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Zura Bio Ltd is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The reporting period covers the three and nine months ended September 30, 2025. The Company is an emerging growth company and a smaller reporting company. As of November 10, 2025, there were 65,023,308 Class A Ordinary Shares outstanding.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(18.0) million | $(20.7) million | $(51.5) million | $(38.8) million |
| Net Loss Attributable to Shareholders | $(20.0) million | $(22.9) million | $(53.5) million | $(36.3) million |
| Loss Per Share (Basic & Diluted) | $(0.21) | $(0.26) | $(0.57) | $(0.52) |
| Cash and Cash Equivalents (Sept 30, 2025) | $139.0 million | |||
| Accumulated Deficit (Sept 30, 2025) | $(207.4) million | |||
| Net Cash Used in Operating Activities (YTD) | $(42.5) million | $(17.3) million |
Material Changes vs. Prior Period
- Research and Development (R&D): R&D expenses increased significantly by 98% ($5.9 million) in Q3 2025 compared to Q3 2024, and by 105% ($16.0 million) on a YTD basis. This increase is primarily driven by the advancement of Phase 2 clinical trials for the lead candidate, tibulizumab, specifically the TibuSHIELD (hidradenitis suppurativa) and TibuSURE (systemic sclerosis) studies.
- General and Administrative (G&A): G&A expenses decreased by 43% ($5.7 million) in Q3 2025 compared to Q3 2024. This decrease was largely due to a $5.9 million non-cash share-based compensation charge related to the modification of awards for the former CEO in the prior year, which did not recur in the current period.
- Other Income/Expense: The Company recognized no change in fair value of private placement warrants in 2025, as all such warrants were exchanged for shares in August 2024. In contrast, Q3 2024 included a $3.9 million loss from the revaluation of these warrants.
- Liquidity: Cash balances decreased from $176.5 million at year-end 2024 to $139.0 million at September 30, 2025, reflecting a net cash outflow of $37.5 million for the nine-month period.
Guidance, Outlook, and Risks
- Clinical Pipeline: The Company is advancing tibulizumab (ZB-106) in two Phase 2 trials. Topline results for TibuSHIELD are expected in Q3 2026, and for TibuSURE in Q4 2026. The Company is also evaluating indications for crebankitug (ZB-168) and torudokimab (ZB-880).
- Liquidity Outlook: Management believes existing cash and cash equivalents ($139.0 million) are sufficient to fund operations through 2027. However, the Company expects to incur significant losses for the foreseeable future and will require additional capital to advance clinical programs and commercialize products.
- Management Changes: On October 10, 2025, CEO Robert Lisicki commenced a medical leave of absence. Kim Davis (COO) was appointed Interim CEO. Eric Hyllengren succeeded Verender Badial as CFO in July 2025.
- Contingencies and Risks:
- Internal Review: The Audit Committee is conducting an internal review of agreements with BAFFX17 and Stone Peach. As of September 30, 2025, the Company has not made a requested $5.0 million milestone payment to BAFFX17 or settled a $5.0 million Put Option exercise by Stone Peach pending the outcome of this review.
- License Obligations: The Company has significant contingent milestone and royalty obligations to Eli Lilly and Pfizer. A $3.0 million payment to Lilly is due if a specific financing threshold is not met by December 7, 2025.
- Regulatory and Trade: Risks include potential FDA delays due to government shutdowns, international trade tariffs affecting supply chains, and reliance on third-party manufacturers (including WuXi Biologics in China).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $139.0 million cash balance against the projected burn rate, considering the significant increase in R&D spend for Phase 2 trials.
- Contingent Liabilities: Monitor the status of the internal audit regarding BAFFX17 and Stone Peach, specifically the potential $5.0 million payment obligations and the impact on the balance sheet.
- Lilly License Status: Confirm whether the $3.0 million payment to Lilly regarding the Z33 financing threshold will be triggered by the December 7, 2025 deadline.
- Clinical Timelines: Track enrollment and data readout dates for the TibuSHIELD and TibuSURE Phase 2 trials, as delays could materially impact capital requirements.
- Management Continuity: Assess the impact of the CEO's medical leave and the interim leadership structure on strategic execution.